The Shigella flexneri effector IpaH1.4 facilitates RNF213 degradation and protects cytosolic bacteria against interferon-induced ubiquitylation
A central signal that marshals host defense against many infections is the lymphocyte-derived cytokine interferon-gamma (IFNγ). The IFNγ receptor is expressed on most human cells, and its activation leads to the expression of antimicrobial proteins that execute diverse cell-autonomous immune programs. One such immune program consists of the sequential detection, ubiquitylation, and destruction of intracellular pathogens. Recently, the IFNγ-inducible ubiquitin E3 ligase RNF213 was identified as a pivotal mediator of such a defense axis. RNF213 provides host protection against viral, bacterial, and protozoan pathogens. To establish infections, potentially susceptible intracellular pathogens must have evolved mechanisms that subdue RNF213-controlled cell-autonomous immunity. In support of this hypothesis, we demonstrate here that a causative agent of bacillary dysentery, <i>Shigella flexneri</i>, uses the type III secretion system (T3SS) effector IpaH1.4 to induce the degradation of RNF213. <i>S. flexneri</i> mutants lacking IpaH1.4 expression are bound and ubiquitylated by RNF213 in the cytosol of IFNγ-primed host cells. Linear (M1-) and lysine-linked ubiquitylation of <i>S. flexneri</i> requires RNF213 but is independent of the linear ubiquitin chain assembly complex (LUBAC). We find that ubiquitylation of <i>S. flexneri</i> is insufficient to kill intracellular bacteria, suggesting that <i>S. flexneri</i> employs additional virulence factors to escape from host defenses that operate downstream from RNF213-driven ubiquitylation. In brief, this study identified the bacterial IpaH1.4 protein as an inhibitor of mammalian RNF213 and highlights evasion of RNF213-driven immunity as a characteristic of the human-tropic pathogen <i>Shigella</i>.
Authors
- Samantha Skavicus
- Mary S Dickinson (ORCID: https://orcid.org/0000-0002-7227-9640)
- Neal M. Alto (ORCID: https://orcid.org/0000-0002-7602-3853)
- Nicholas S. Heaton (ORCID: https://orcid.org/0000-0002-5307-3428)
- Shruti Apte (ORCID: https://orcid.org/0000-0003-0477-9667)
- Jörn Coers (ORCID: https://orcid.org/0000-0001-8707-4608)
- Maarten F. de Jong (ORCID: https://orcid.org/0000-0003-2278-286X)
- Yifeng Zhang (ORCID: https://orcid.org/0000-0002-2832-2277)
- Luz Saavedra-Sanchez (ORCID: https://orcid.org/0000-0002-4362-8928)
Institutions
- Duke Medical Center (US)
- Duke University Hospital (US)
- The University of Texas Southwestern Medical Center (US)
Publication Details
- Journal
- eLife
- Published
- 2024-11-20
- DOI
- https://doi.org/10.7554/elife.102714
- Citations
- 7
- Primary Topic
- interferon and immune responses
- Type
- article
- Field-Weighted Citation Impact
- 1.68
Funders
- National Institutes of Health